세계의 급성 심근경색 시장 보고서(2025년)
Acute Myocardial Infarction Global Market Report 2025
상품코드 : 1750890
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

급성 심근경색 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 이 기간의 주요 동향에는 AI를 활용한 조기 발견 시스템, 웨어러블 ECG 모니터링 기기, 나노기술을 활용한 약물전달, 심장 조직의 3D 바이오프린팅, 고급 로봇 지원 심장 수술 등이 있습니다.

고혈압의 유병률 상승은 급성 심근경색 시장 성장을 크게 견인할 것으로 예측됩니다. 혈관 합병증의 주요 위험 요인입니다. 고혈압 사례 증가는 책상 작업으로 인한 앉기 쉬운 행동, 과도한 스크린 사용 시간, 최소한의 신체 활동과 같은 현대 라이프 스타 일 요인에 기인합니다. 고혈압은 동맥을 손상시키고 플라크의 축적을 촉진하고 혈전 위험을 높입니다. 예를 들어, 호주 통계청의 보고서에 따르면 호주의 고혈압 유병률은 2022년에 11.6%(약 300만 명)에 달했습니다.

급성 심근경색 시장의 주요 기업은 제품 라인업을 강화하고 치료 성적을 향상시키기 위해 규제 당국의 승인 취득에 점점 주력하고 있습니다. FDA 및 EMA와 같은 규제 당국의 승인은 의약품 및 의료기기가 필요한 안전성, 효능 및 품질 기준을 충족하는 데 필수적입니다. 예를 들어, 2025년 3월, 중국의 바이오 의약품 회사인 Sungen Biomedical은 단일클론항체 의약품 SGC001의 FDA Fast Track Designation을 취득했습니다. 이 의약품은 급성 심근경색의 응급치료제로서는 처음으로, 심근세포의 아폽토시스를 억제하고 허혈부위의 혈류를 개선하는 유망한 전임상시험 결과를 나타내고 있습니다. 패스트트랙 인증을 받으면 Sungen Biomedical은 승인 과정을 신속하게 진행할 수 있으며 AMI 환자에게 구명이 가능한 이 치료제에 신속하게 액세스할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Acute myocardial infarction (MI), commonly known as a heart attack, occurs when there is a sudden reduction or complete cessation of blood flow to one or more coronary arteries, resulting in the death of heart muscle tissue. This is typically caused by the rupture of atherosclerotic plaques, leading to a blockage in the blood flow.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of myocardial infarction are ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). STEMI is a more severe form of heart attack, characterized by a complete blockage of a coronary artery, significantly reducing blood flow to the heart muscle. Treatment for acute myocardial infarction involves thrombolytic therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medications. Diagnosis is performed using various methods, including electrocardiograms (ECG), cardiac biomarkers, echocardiography, coronary angiography, MRI, and CT scans. Medications are administered through different routes, including oral, intravenous (IV), subcutaneous, transdermal, and sublingual. The primary end users for these treatments include hospitals, clinics, ambulatory surgical centers, specialty cardiac centers, and research institutes.

The acute myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides acute myocardial infarction market statistics, including acute myocardial infarction industry global market size, regional shares, competitors with an acute myocardial infarction market share, detailed acute myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the acute myocardial infarction industry. This acute myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute myocardial infarction market size has grown strongly in recent years. It will grow from$1.47 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed during the historical period can be linked to a rise in heart diseases associated with smoking, a higher prevalence of hypertension, advancements in emergency medical services, increased awareness of heart disease risk factors, and the early use of aspirin in cardiovascular treatment.

The acute myocardial infarction market size is expected to see strong growth in the next few years. It will grow to$1.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth projected for the forecast period can be attributed to the growing demand for minimally invasive cardiac procedures, increased investment in regenerative medicine for heart repair, the rising prevalence of obesity and diabetes, and an expanding focus on personalized medicine for heart disease. Key trends during this period include AI-driven early detection systems, wearable ECG monitoring devices, nanotechnology-based drug delivery, 3D bioprinting of cardiac tissues, and advanced robotic-assisted cardiac surgeries.

The rising prevalence of hypertension is expected to significantly drive the growth of the acute myocardial infarction (AMI) market. Hypertension, characterized by persistently high blood pressure, is a major risk factor for heart disease, stroke, and other cardiovascular complications. The increase in hypertension cases can be attributed to modern lifestyle factors, such as sedentary behavior from desk jobs, excessive screen time, and minimal physical activity. Hypertension damages the arteries, promotes plaque buildup, and increases the risk of blood clots, all of which can contribute to acute myocardial infarction. For example, according to a report by the Australian Bureau of Statistics, the prevalence of hypertension in Australia reached 11.6% (approximately 3.0 million people) in 2022. As hypertension rates rise, the growth of the acute myocardial infarction market is anticipated to follow suit.

Key players in the acute myocardial infarction market are increasingly focusing on obtaining regulatory approvals to enhance their product offerings and improve treatment outcomes. Regulatory approvals from agencies such as the FDA and EMA are vital in ensuring that drugs and medical devices meet required safety, efficacy, and quality standards. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001. This drug, the first of its kind for the emergency treatment of acute myocardial infarction, has shown promising preclinical results in reducing cardiomyocyte apoptosis and improving blood flow in ischemic areas. The Fast Track status allows Sungen Biomedical to fast-track the approval process, enabling quicker access to this potentially life-saving therapy for AMI patients.

In February 2023, BioCardia Inc., a U.S.-based biotechnology company, extended its partnership with CellProthera to advance the development of ProtheraCytes for treating acute myocardial infarction. BioCardia plans to leverage its Helix transendocardial biotherapeutic delivery system for CellProthera's Phase I/IIb EXCELLENT study, focused on its lead product candidate, ProtheraCytes. CellProthera, a France-based company, specializes in regenerative therapies for AMI, and this partnership aims to develop innovative treatments that could significantly improve heart attack recovery outcomes.

Major players in the acute myocardial infarction market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., and Serca Pharmaceuticals.

North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute myocardial infarction report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute myocardial infarction market consists of revenues earned by entities by providing services such as diagnostic testing, telemedicine consultations, remote patient monitoring, pharmaceutical treatments, and post-acute myocardial infarction (AMI) management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute myocardial infarction market also includes sales of pharmaceutical drugs, medical devices, diagnostic tools, wearable cardiac monitors, and telemedicine platforms for remote cardiac care. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Myocardial Infarction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for acute myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Acute Myocardial Infarction Market Characteristics

3. Acute Myocardial Infarction Market Trends And Strategies

4. Acute Myocardial Infarction Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Myocardial Infarction Growth Analysis And Strategic Analysis Framework

6. Acute Myocardial Infarction Market Segmentation

7. Acute Myocardial Infarction Market Regional And Country Analysis

8. Asia-Pacific Acute Myocardial Infarction Market

9. China Acute Myocardial Infarction Market

10. India Acute Myocardial Infarction Market

11. Japan Acute Myocardial Infarction Market

12. Australia Acute Myocardial Infarction Market

13. Indonesia Acute Myocardial Infarction Market

14. South Korea Acute Myocardial Infarction Market

15. Western Europe Acute Myocardial Infarction Market

16. UK Acute Myocardial Infarction Market

17. Germany Acute Myocardial Infarction Market

18. France Acute Myocardial Infarction Market

19. Italy Acute Myocardial Infarction Market

20. Spain Acute Myocardial Infarction Market

21. Eastern Europe Acute Myocardial Infarction Market

22. Russia Acute Myocardial Infarction Market

23. North America Acute Myocardial Infarction Market

24. USA Acute Myocardial Infarction Market

25. Canada Acute Myocardial Infarction Market

26. South America Acute Myocardial Infarction Market

27. Brazil Acute Myocardial Infarction Market

28. Middle East Acute Myocardial Infarction Market

29. Africa Acute Myocardial Infarction Market

30. Acute Myocardial Infarction Market Competitive Landscape And Company Profiles

31. Acute Myocardial Infarction Market Other Major And Innovative Companies

32. Global Acute Myocardial Infarction Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Myocardial Infarction Market

34. Recent Developments In The Acute Myocardial Infarction Market

35. Acute Myocardial Infarction Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기